Erlotinib is a targeted therapy drug primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which works by blocking the activity of EGFR, a protein that promotes the growth of cancer cells.
